ARGX ArGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences



February 27, 2023



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:

  • Cowen 43rd Annual Healthcare Conference. Fireside chat on Monday, March 6, 2023 at 10:30 a.m. ET in Boston, MA.



  • Raymond James 44th Annual Institutional Investors Conference. Presentation on Tuesday, March 7, 2023 at 1:05 p.m. ET in Orlando, FL.



Additional information regarding these events will be available on the Investors section of the argenx website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit and follow us on , , and .

For further information, please contact:

Media:

Kelsey Kirk

Investors:

Beth DelGiacco



EN
27/02/2023

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...

2h / 30m 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of My...

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

August 12, 2025 1 EN
Free Trial
ARGX ARGEN-X SE

Argen X SE: 1 director

A director at Argen X SE sold 1,630 shares at 601.990EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

08/11/25 August 11, 2025 1 EN
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Wim Lewi
XIOR XIOR STUDENT HOUSING N.V.
ARCAD ARCADIS NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
CTPNV CTP NV
08/07/25 August 7, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx Upping our FY25 estimates after a solid 2Q25 beat

Following argenx' 2Q25 results with Vyvgart sales coming in at $ 949m, and beating CSS by 10%, we update our model, upping our Vyvgart sales estimates for FY25 to $ 3.98b (from $ 3.61b, Visible Alpha CSS: $ 3.97b). We factor in potential competition from IMAAVY (J&J), though we continue to see Vyvgart as the better product, and model approx. 12% q/q growth for 3Q25 and 4Q25. Additionally, we slightly tweak our CIDP numbers bringing us to higher peak sales ($ 4.22b vs. $ 3.76b). All in all, our t...

08/07/25 August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch